PD-1/PD-L1 Inhibitors Archives

Tag: PD-1/PD-L1 Inhibitors

A protein found on T cells (a type of immune cell) that helps keep the body’s immune responses in check. When PD-1 is bound to another protein called PD-L1, it helps keep T cells from killing other cells, including cancer cells.

Some anticancer drugs, called immune checkpoint inhibitors, are used to block PD-1 (inhibited). When this protein is blocked, the “brakes” on the immune system are released and the ability of T cells to kill cancer cells is increased.

Clinical Trials and Research, TreatmentAdvanced neuroendocrine cancer, Anti-angiogenic therapy, Atezolizumab (Tecentriq), Avelumab (Bavencio), Avistan, Bavencio, Bevacizumab, Cisplatin, Colorectal cancer, DLL3, EGFR, Epidermal growth factor receptor (EGFR), Fluoropyrimidine, Head and Neck Cancer, Hodgkin lymphoma, Immunotherapy, Ipilimumab (Yervoy), Keytruda, Lanreotide, Melanoma, Microsatellite instability-high (MSI-H), Neuroendocrine cancer, Neuroendocrine carcinoma (NEC), Neuroendocrine tumour (NET), Nivolumab (Opdivo), Non-small cell lung cancer (NSCLC), Paraganglioma, PD-1/PD-L1 Inhibitors, PDR001, Pembrolizumab (Keytruda), Pemetrexed disodium, Pheochromocytoma, Solid tumour, Squamous cell carcinoma, Tecentriq (Atezolizumab), Tumour mutational burden (TMB), Typical lung NET, Yervoy

Immunotherapy and Neuroendocrine Neoplasms

By Ronny Allan Sep 25, 2025 8 Comments

Clinical Trials and ResearchAdvanced neuroendocrine cancer, Atezolizumab (Tecentriq), Avistan, Bevacizumab, Clinical trial, Immunotherapy, Monoclonal antibodies, PD-1/PD-L1 Inhibitors, Vascular endothelial growth factor (VEGF)

Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial

By Ronny Allan Jul 20, 2022 0 Comments

Background Well differentiated NETs have been described as an "immunological desert" in recent years mainly due to the poor response rate data coming out of clinical trials of immunotherapy drugs. Poorly differentiated NEC has favoured better but mainly in the more obscure types. Which is why these data of a combo treatment containing one immunotherapy drug caught my eye. What is atezolizumab? It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. It's a Programmed cell death protein -1 (PD-1)/ Ligand 1 (PD-L1) inhibitor. A drug that binds to the protein PD-L1 to help immune cells…

Clinical Trials and Research, TreatmentDostarlimab, Immunotherapy, Monoclonal antibodies, Neuroendocrine carcinoma (NEC), PD-1/PD-L1 Inhibitors, Small cell lung cancer (SCLC)

Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma

By Ronny Allan Jun 08, 2022 0 Comments

BackgroundFollowing the Americal Society of Clinical Oncology (ASCO) conference in June 2022 (ASCO is the biggest Oncology event in the world), the media widely featured the results of the Phase 2 clinical trial of the drug Dostarlimab, an anti–PD-1 monoclonal antibody. The media often looks for headline-grabbing stories and this was one of them. One UK TV outlet said they may have found the cure for cancer, which is a reckless statement when you look at the size and boundary of the clinical trial referenced. The detail is, that this was a phase 2 trial for "rectal adenocarcinoma", but specifically…